Literature DB >> 23252646

Does Rh immune globulin suppress HLA sensitization in pregnancy?

Richard M Kaufman1, Karen S Schlumpf, David J Wright, Darrell J Triulzi.   

Abstract

BACKGROUND: How Rh immune globulin (RhIG) prevents sensitization to D antigen is unclear. If RhIG Fc delivers a nonspecific immunosuppressive signal, then RhIG may inhibit sensitization to antigens other than D. HLA antibody prevalence was compared in previously pregnant D- versus D+ women to investigate whether RhIG suppresses HLA sensitization. STUDY DESIGN AND METHODS: In the Leukocyte Antibody Prevalence Study (LAPS), 7920 volunteer blood donors were screened for anti-HLA and surveyed about prior pregnancies and transfusions. A secondary analysis of the LAPS database was performed.
RESULTS: D- women not more than 40 years old (presumed to have received antenatal with or without postpartum RhIG in all pregnancies) had a significantly lower HLA sensitization rate than D+ women (relative risk, 0.58; 95% confidence interval [CI], 0.40-0.83). When stratified by deliveries (one, two, three, or four or more), D- women not older than 40 were HLA sensitized less often than D+ women in every case. In contrast, a clear relationship between D type and HLA sensitization was not seen in older previously pregnant women whose childbearing years are presumed to have preceded the use of routine RhIG prophylaxis. In a multivariable logistic regression model, D- women not more than 40 years old remained significantly less likely to be HLA sensitized compared with D+ women after adjusting for parity, time from last pregnancy, lost pregnancies, and transfusions (odds ratio [OR], 0.55; 95% CI, 0.34-0.88).
CONCLUSION: Consistent with a nonspecific immunosuppressive effect of RhIG, younger previously pregnant D- women were less likely than previously pregnant D+ women to be HLA sensitized.
© 2012 American Association of Blood Banks.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23252646      PMCID: PMC3609922          DOI: 10.1111/trf.12049

Source DB:  PubMed          Journal:  Transfusion        ISSN: 0041-1132            Impact factor:   3.157


  27 in total

1.  Efficient IgG-mediated suppression of primary antibody responses in Fcgamma receptor-deficient mice.

Authors:  M C Karlsson; S Wernersson; T Diaz de Ståhl; S Gustavsson; B Heyman
Journal:  Proc Natl Acad Sci U S A       Date:  1999-03-02       Impact factor: 11.205

2.  On the immunologic basis of Rh immune globulin (anti-D) prophylaxis.

Authors:  Belinda M Kumpel
Journal:  Transfusion       Date:  2006-09       Impact factor: 3.157

3.  Fetomaternal transplacental hemorrhage during pregnancy and after delivery.

Authors:  J M Bowman; J M Pollock; L E Penston
Journal:  Vox Sang       Date:  1986       Impact factor: 2.144

4.  A prospective study of the incidence, time of appearance and significance of anti-paternal lymphocytotoxic antibodies in human pregnancy.

Authors:  L Regan; P R Braude; D P Hill
Journal:  Hum Reprod       Date:  1991-02       Impact factor: 6.918

5.  Antibody-mediated immune suppression to the Rh factor: animal models suggesting mechanism of action.

Authors:  W Pollack; J G Gorman; H J Hager; V J Freda; D Tripodi
Journal:  Transfusion       Date:  1968 May-Jun       Impact factor: 3.157

Review 6.  The prevention of Rh immunization.

Authors:  J M Bowman
Journal:  Transfus Med Rev       Date:  1988-09

7.  Studies on Rh prophylaxis. II. Rh immune prophylaxis after transfusion with Rh-positive blood.

Authors:  W Pollack; W Q Ascari; J F Crispen; R R O'Connor; T Y Ho
Journal:  Transfusion       Date:  1971 Nov-Dec       Impact factor: 3.157

8.  Leukocyte reduction and ultraviolet B irradiation of platelets to prevent alloimmunization and refractoriness to platelet transfusions.

Authors: 
Journal:  N Engl J Med       Date:  1997-12-25       Impact factor: 91.245

9.  Epidemiology of Rh hemolytic disease of the newborn in the United States.

Authors:  G F Chávez; J Mulinare; L D Edmonds
Journal:  JAMA       Date:  1991-06-26       Impact factor: 56.272

10.  The natural history of fetomaternal alloimmunization to the platelet-specific antigen HPA-1a (PlA1, Zwa) as determined by antenatal screening.

Authors:  L M Williamson; G Hackett; J Rennie; C R Palmer; C Maciver; R Hadfield; D Hughes; S Jobson; W H Ouwehand
Journal:  Blood       Date:  1998-10-01       Impact factor: 22.113

View more
  2 in total

1.  Antibody-mediated immune suppression by antigen modulation is antigen-specific.

Authors:  Cheryl L Maier; Amanda Mener; Seema R Patel; Ryan P Jajosky; Ashley L Bennett; Connie M Arthur; Jeanne E Hendrickson; Sean R Stowell
Journal:  Blood Adv       Date:  2018-11-13

2.  Anti-D monoclonal antibodies from 23 human and rodent cell lines display diverse IgG Fc-glycosylation profiles that determine their clinical efficacy.

Authors:  Belinda M Kumpel; Radka Saldova; Carolien A M Koeleman; Jodie L Abrahams; Agnes Hipgrave Ederveen; Kathryn L Armour; Natalia I Olovnikova; Gestur Vidarsson; Rick Kapur; Pauline M Rudd; Manfred Wuhrer
Journal:  Sci Rep       Date:  2020-01-30       Impact factor: 4.379

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.